Anthropic, the multi-billion-dollar artificial intelligence firm has appointed Dr. Vasant “Vas” Narasimhan, the chief executive officer of Swiss pharmaceutical giant Novartis, to its board of directors to solidify its governance.
The Anthropic Long-Term Benefit Trust’s addition of a veteran of the highly regulated life sciences sector to its leadership marks a strategic shift that gives Trust-appointed directors a majority on the board.
This structure is designed to ensure the company’s “constitutional AI” mission,prioritizing safety and public benefit, remains intact even as the startup scales toward a reported $380 billion valuation.
For Narasimhan, a first-generation Indian American, the role is a culmination of a career built at the intersection of breakthrough science and social impact. Born in Pittsburgh to Iyengar Brahmin parents who emigrated from Tamil Nadu in the 1960s, Narasimhan’s upbringing was steeped in Indian heritage.
His parents were instrumental in founding the Shri Venkateshwara temple in Penn Hills, and Narasimhan has frequently credited his grandmother’s resilience in rural India as a primary inspiration for his humanitarian approach to leadership.
His academic and professional ties to the subcontinent are extensive. Before rising to the top of Novartis, Narasimhan spent months in Kolkata working with street children and child laborers.
Read: MacGyver in the Age of AI = Penn Medicine Scientists
His medical and policy training, earned through an MD from Harvard Medical School and an MPP from the John F. Kennedy School of Government, was frequently applied to public health crises in India, where he worked on large-scale HIV/AIDS and malaria programs.
“Vas brings something rare to our board,” said Daniela Amodei, co-founder and President of Anthropic. She noted that his experience overseeing the approval of more than 35 novel medicines at Novartis provides a blueprint for how Anthropic intends to handle the “dual-use” risks of AI, particularly in the biological sciences.
As AI models like Claude become more capable of assisting in complex drug discovery and genomic research, the need for clinical-grade oversight has become paramount.
Narasimhan’s presence on a board that includes tech luminaries like Instagram co-founder Mike Krieger and Netflix co-founder Reed Hastings suggests that Anthropic is treating the “release” of AI models with the same rigorous safety standards applied to life-saving pharmaceuticals.
With Narasimhan’s guidance, Anthropic aims to bridge the gap between Silicon Valley’s “move fast” culture and the “do no harm” ethics of modern medicine.